GGrantIndex
← Leaderboards

Charles Stewart Kamen

University Of Rochester

Google Scholar ↗PubMed ↗ORCID ↗
$6,665,831
Attributed
$13,273,717
Total exposure
6
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.6M · FY2015–25
$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,273,717 · 6

By mechanism

UH3$7,201,689 · 1
R01$2,317,650 · 1
UG3$2,064,137 · 1
K07$830,495 · 1
R34$827,246 · 1
R13$32,500 · 1

Top collaborators

Most similar at University Of Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms”

Research focus

Malignant NeoplasmsResponseDesignCancer PatientCancer TypeLinkPsychological DistressClinical TrialsCancer TherapyDiagnosisMortalityQuality Of LifeFundingInnovationAftercareCancer SurvivorAnticancer ResearchCancer ControlEnrollmentCheckpoint TherapyCancer DiagnosisImmunotherapyBehavioralDiscrimination

Grant awards (17)

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$2,425,687
UH3 · FY2025 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$766,294
R01 · FY2025 · CA
Adapting the FOCUS Program for High-Risk Cancer Patients and Caregivers$271,980
R34 · FY2025 · CA · contact PI
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$2,281,096
UH3 · FY2024 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$735,428
R01 · FY2024 · CA
Adapting the FOCUS Program for Sexual and Gender Minority (SGM) Cancer Patients and Caregivers$261,095
R34 · FY2024 · CA · contact PI
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$2,494,906
UH3 · FY2023 · CA
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$815,928
R01 · FY2023 · CA
Adapting the FOCUS Program for Sexual and Gender Minority (SGM) Cancer Patients and Caregivers$294,171
R34 · FY2023 · CA · contact PI
The Science of Cancer Health Equity for Sexual and Gender Minority Communities$32,500
R13 · FY2023 · CA · contact PI
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$1,004,241
UG3 · FY2022 · CA
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting$1,059,896
UG3 · FY2021 · CA
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors$166,099
K07 · FY2019 · CA · contact PI
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors$166,099
K07 · FY2018 · CA · contact PI
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors$166,099
K07 · FY2017 · CA · contact PI
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors$166,099
K07 · FY2016 · CA · contact PI
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors$166,099
K07 · FY2015 · CA · contact PI